Date: April 2, 2026 Stock price: ~30.39|Marketcap: 2.76B | Shares: 90.9M FY ends: December (calendar year) FY25 Revenue: $490.7M (+110.3% YoY) | FILSPARI FY25: $322.0M (+144% YoY)
Let me tell you, the numbers on this company got my attention in a big way. FILSPARI revenue went from $132M in FY24 to $322M in FY25 — that's 144% growth! And the annualized run-rate from Q4 is now $413M. This is a specialty pharma company with 98% gross margins and revenue accelerating at scale — annual growth went from 33% (FY23) to 60% (FY24) to 110% (FY25). That is such an extraordinary trajectory!
But — and this is important — there's a binary FDA event on April 13 that could move the stock 30-40% in either direction. The FSGS approval decision is 11 days away. If approved, FILSPARI becomes the first and only drug for FSGS and the addressable market roughly doubles. If rejected, the company still has a strong IgAN franchise but the growth trajectory changes dramatically.
I'm extremely interested in this company. The numbers are among the best I've seen outside of tech/SaaS. But I have to be honest — I'm not a biotech expert, and binary FDA events make me uncomfortable. I'd want a starter position here, with the intention to add significantly if FSGS is approved and the launch goes well. Conviction: Medium-High. The numbers are screaming "buy," but the binary event in 11 days demands some caution.
| Quarter | Revenue ($M) | YoY % | QoQ % | GM% [GAAP] | OpM% [GAAP] | OpM% [Non-GAAP] | EPS (Non-GAAP) |
|---|---|---|---|---|---|---|---|
| Q1 FY24 | 41.4 | +34.0% | -8.2% | 96.4% | -336% | — | — |
| Q2 FY24 | 54.1 | +68.0% | +30.7% | 96.1% | -125% | — | — |
| Q3 FY24 | 62.9 | +69.5% | +16.3% | 97.5% | -89% | — | — |
| Q4 FY24 | 74.8 | +65.9% | +18.9% | 96.5% | -81% | — | — |
| Q1 FY25 | 81.7 | +97.3% | +9.2% | 94.2% | -52% | -22.5% | — |
| Q2 FY25 | 114.4 | +111.5% | +40.0% | 98.7% | -11% | +10.5% | $0.13 |
| Q3 FY25 | 164.9 | +162.2% | +44.1% | 99.0% | +15% | +31.5% | $0.59 |
| Q4 FY25 | 129.7 | +73.4% | -21.3% | 98.0% | -25% | -2.2% | $0.37 |
Now, I know what you're thinking — "Q4 dropped sequentially!" Don't be fooled. The Q3 spike to $164.9M was inflated by a $51.7M one-time CSL Vifor license milestone. If you strip out the lumpy license revenue and look at net product sales — which is what actually matters — the picture is completely different:
| Quarter | FILSPARI | Tiopronin | Net Product | QoQ % | YoY % |
|---|---|---|---|---|---|
| Q1 FY25 | $55.9M | $20.0M | $75.9M | — | +90% |
| Q2 FY25 | $71.9M | $23.0M | $94.9M | +25% | +82% |
| Q3 FY25 | $90.9M | $22.3M | $113.2M | +19% | +86% |
| Q4 FY25 | $103.3M | $23.3M | $126.6M | +12% | +72% |
Product revenue grew every single quarter! FILSPARI went from $55.9M to $103.3M sequentially through the year — that's +85% within the year, quarter by quarter! The Q4 sequential product growth of +12% reflects normal seasonal patterns, not deceleration.
| Quarter | FILSPARI ($M) | QoQ % | YoY % |
|---|---|---|---|
| Q1 FY24 | 19.8 | — | — |
| Q2 FY24 | 27.1 | +37% | — |
| Q3 FY24 | 35.6 | +31% | — |
| Q4 FY24 | 49.6 | +39% | — |
| Q1 FY25 | 55.9 | +13% | +182% |
| Q2 FY25 | 71.9 | +29% | +165% |
| Q3 FY25 | 90.9 | +26% | +155% |
| Q4 FY25 | 103.3 | +14% | +108% |
FILSPARI annual: $132.2M (FY24) -> 322.0M(FY25) = * * +144413M**.
The YoY deceleration from 182% to 108% is totally expected — it's base effect math as the launch matures. What matters is the absolute dollar adds are enormous. FILSPARI added $190M of revenue in a single year on a drug launched in February 2023. That is just a really, really impressive commercial ramp!
| Year | Revenue | YoY % | Assessment |
|---|---|---|---|
| FY22 | $109.4M | — | Pre-FILSPARI era |
| FY23 | $145.3M | +33% | FILSPARI launch year |
| FY24 | $233.2M | +60% | Accelerating |
| FY25 | $490.7M | +110% | Accelerating further! |
33% -> 60% -> 110%. That's three consecutive years of accelerating annual revenue growth. How often do you see that??? At this scale???
| Year | Annual OCF ($M) | Annual FCF ($M) | Assessment |
|---|---|---|---|
| FY23 | -$325.4M | — | Peak cash burn |
| FY24 | -$230.0M | — | Improving |
| FY25 | +$37.8M | -$20.4M | First positive OCF year! |
FY25 is the company's first year of positive operating cash flow in its history. FCF is still slightly negative (-$20.4M) because of $58.2M in capitalized royalty/intangible investments, but the core business is cash-flow positive. That's the inflection.
Revenue accelerating at scale. FY23 +33%, FY24 +60%, FY25 +110%. Three years of accelerating growth on a base that's now approaching $500M. You just don't see this very often!
Gross margins of 98%. This is specialty pharma — basically no cost of goods. Higher gross margins than any SaaS company I've ever owned! The entire revenue increase drops to gross profit.
FILSPARI product-market fit is undeniable. 144% YoY growth, KDIGO first-line endorsement (the guideline doctors actually follow!), published clinical data in The Lancet showing 31% complete remission vs 11% for comparator. This isn't a "maybe it works" drug — the real-world evidence is confirming the clinical trial results.
Record patient start forms (PSFs) in Q4. 908 new PSFs, up 24% from 731 in Q3. This is a leading indicator — prescriptions in the pipeline that haven't converted to revenue yet. It tells me Q1 FY26 should be strong.
Profitability inflection. Non-GAAP EPS of $0.91 for FY25 (first year of non-GAAP profitability). FY25 operating cash flow positive for the first time ever. The company is reaching escape velocity.
Dilution slowing dramatically. Only +1.9M new shares in FY25 vs +6.0M in FY24 and +12.5M in FY23. As the company approaches self-funding, it doesn't need to sell stock anymore.
Valuation is extremely attractive. P/S of 5.7x on 110% revenue growth gives a PEG of 0.05. That is just absurdly cheap relative to the growth rate. Non-GAAP P/E of ~31x is reasonable for this growth profile. Rule of 40 score of 117% — exceptional.
REMS simplification (August 2025). Monitoring went from monthly to quarterly — removes a major adoption friction that was holding back prescriptions. This directly drives the PSF acceleration we're seeing.
Binary FSGS event on April 13. I hate binary outcomes. The PDUFA date is 11 days away. If FSGS is rejected, the stock could drop 30-40%. The FDA extended the review period (Major Amendment), which introduces uncertainty. However — no AdCom was scheduled, which is typically a bullish signal. No safety or manufacturing concerns were raised. Analysts seem moderately optimistic.
I don't know pharma. I'm not a techie and I don't understand most of what my tech companies do, but I understand SaaS metrics deeply. Pharma is a different animal — FDA approvals, clinical trial readouts, gross-to-net adjustments, REMS programs. The learning curve is steep for me.
Competitive intensification in IgAN. Novartis launched Vanrafia (atrasentan) in April 2025 — no REMS, which is a convenience advantage for doctors. Voyxact (sibeprenlimab) was approved in November 2025. Fabhalta coming in 2026. The IgAN market went from FILSPARI-only to four approved drugs in less than two years. Now, the total market is growing at 30% CAGR ($730M -> $878M already), so there's room for multiple drugs. FILSPARI has the strongest clinical data and the KDIGO endorsement. But market share will be pressured.
GTN headwind compresses net revenue. Management guided mid-20% gross-to-net for FY26 vs ~20% in FY25. Every 500bps of GTN expansion on a $400M+ FILSPARI base is about $20M of net revenue drag. This partially offsets volume growth. It's real money.
SG&A growing fast. Q4 FY25 SG&A was $101.7M, up 46% YoY. Full-year SG&A was $337M, up 28%. They're investing ahead of the FSGS launch — which makes sense if approved. But if rejected, that's an overhang.
Convertible debt. $311.7M in convertible notes. Terms not fully disclosed. Net cash position is only 11.1M(322.8M cash - $311.7M debt). If conversion price is in the current stock price range, dilution could be significant.
No quarterly guidance. Management provides only directional annual commentary ("meaningful growth"). This means I can't track beat/miss patterns quarter to quarter, which is one of my key tools for assessing management credibility.
| Indicator | Current | Signal |
|---|---|---|
| FILSPARI PSFs | 908 (Q4, all-time high, +24% QoQ) | Bullish — prescriptions in pipeline |
| FILSPARI revenue | +108% YoY (Q4) vs +73% total | Bullish — product growing faster than consolidated |
| A/R growth | $80.1M (+195% YoY) | Watch — growing 2.7x revenue; collection cycle stretch? |
| Cash position | 322.8M(+68M QoQ) | Bullish — cash building |
No bearish divergence. Every leading indicator is pointing up. The PSF count of 908 is the most important number in the whole analysis — it tells you what Q1 FY26 revenue is going to look like.
| Metric | Value | Assessment |
|---|---|---|
| P/S (TTM) | 5.7x | Mid-range commercial biotech |
| P/S (FY26E $600M) | 4.6x | Cheap |
| P/E (Non-GAAP FY25) | ~31x | Fair for 110% growth |
| PEG (P/S / Growth%) | 0.05x | Absurdly cheap |
| Rule of 40 | 117% | Exceptional |
The PEG of 0.05 is among the most attractive I've seen. The market is either pricing in FSGS rejection, severe competitive erosion, or simply hasn't caught up with the financial inflection. If FSGS is approved, FY26 revenue could reach $650-800M and the stock could re-rate to $4-5B market cap.
Atlas scored this 4/5 conviction and called it "deeply discounted to the growth rate." I largely agree with that assessment. The numbers are exceptional — 110% revenue growth, 98% gross margins, profitability inflection, record patient starts. The valuation is clearly cheap.
Where I add nuance: I'm slightly more cautious about the binary FSGS event. Eleven days before a major FDA decision is an uncomfortable time to initiate a position. I'd rather know the outcome first. The IgAN franchise alone is probably worth the current market cap, which means downside is limited even if FSGS is rejected — but I don't like surprises. I'd start smaller than Atlas's implied conviction and add aggressively post-approval.
I also think Atlas underweights the GTN headwind. Mid-20% vs ~20% might sound small, but on a $400M+ FILSPARI base, that's $20-25M in net revenue drag. It's the kind of thing that makes the revenue growth number look worse than the underlying volume growth.
Starter position: 2-3%. The numbers are exceptional, but the binary FSGS event and my unfamiliarity with pharma economics argue for caution. If FSGS is approved on April 13, I would add aggressively to 5-7% and potentially higher based on the FY26 launch trajectory. If rejected, I would hold the starter — the IgAN franchise justifies the current valuation on its own.
Travere Therapeutics has the revenue growth profile of my best SaaS holdings (110% YoY, accelerating), better gross margins (98%), and a valuation that's cheaper than anything in my portfolio on a growth-adjusted basis. FILSPARI is a real drug with real clinical data, real guideline endorsements, and real revenue momentum — 908 new patient start forms in Q4 is an all-time high. The company just turned OCF-positive for the first time in its history.
The catch? It's pharma, not SaaS. Binary events make me nervous. And there's a major FDA decision in 11 days that could move the stock 30-40% in either direction. But you know what? If the numbers are this good and the valuation is this cheap, you can't just ignore it because it's not your comfort zone. The world changes, and you have to change with it.
Best,
Saul
First coverage. Stock analysis based on scout brief 2026-04-01. No prior position. Market cap: ~2.76B(90.9Msharesx 30.39). Current stock price as of early April 2026. Transcript for Q4 FY25 earnings call was unavailable — analysis based on press release, EDGAR XBRL, and corporate update data.